Bachem: Press Releases
Peptide News from Bachem: pNA and AMC Substrates in Milligram to Multi-Gram Quantities
To enable quantitative studies of enzyme kinetics, enzyme substrates have been manufactured bearing chromogenic or fluorogenic moieties to allow for visualization using ultraviolet...
29 New Products Now Available from Bachem
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include...
Six New Products Available from Bachem
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include...
Ten New Products Available from Bachem
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include human...
Bachem and Atheris Collaborate on Melusine® Venom Peptide
Bachem has announced that the company has concluded an agreement with Atheris Laboratories to market their Melusine® libraries, consisting of natural products isolated from animal venoms....
Bachem - Your Partner for Resins for SPPS
Solid-phase synthesis, especially the more convenient Fmoc variant, has become the routine method for assembling peptides. Standard resins such as Wang resin yield the 'free peptide',...
Bachem Releases Half-Year Results for 2010
In the first half of 2010, sales of the Bachem Group fell to CHF73.9m as a result of the difficult market conditions. Trends in the most important business areas Generics in particular...
Ten New Products are Available from Bachem
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include atrial...
Bachem - Your Partner for Bioactive Peptides
Thymosin β4 is a 43 amino acid peptide. It is the most abundant member of the β-thymosin family in mammalian tissue and is regarded as the main intracellular G-actin sequestering...
Bachem Divests Stake in Polyphor
Bachem has announced that the company, on 16 June 2010, sold its complete stake in Polyphor to Ingro Finanz, which hereby increased its stake in Polyphor to 29%. The involved parties...
Bachem to Supply ISA Pharmaceuticals with Finished Dosage Forms of Immunotherapeutic HPV-SLP for Phase III Clinical Trials
Bachem and ISA Pharmaceuticals have announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of finished dosage forms of ISA...
Bachem - Your Partner for the Biotinylation of Peptides
The complex formation between biotin and avidin or streptavidin is one of the strongest and most specific non-covalent interactions of a low-molecular weight compound with a protein. In...
Bachem Releases New Receptor Antagonist, Building Blocks for Peptide Synthesis and Immunology Products
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include the PAC1...
Bachem Confirms High Profitability in the 2009 Business Year
In 2009, despite difficult market conditions, the Bachem Group achieved sales of CHF181.8 million. Compared with the previous year, this corresponds to a sales decline of only 5.6% in...
Bachem - Your Reliable Manufacturer of Custom Peptides
Bachem, the number one in the production of peptides at any scale, is and will remain your ideal partner for custom synthesis. Our proficient peptide synthesis techniques coupled with...
New from Bachem: Liraglutide, Rat Alarin, ACTH Peptides and a High Sensitivity EIA Kit
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include Liraglutide, a...
Bachem Releases New Building Blocks and Immunology Products
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include the novel...
mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases
mondoBIOTECH and Bachem have announced the conclusion of a longterm cooperation. In the frame of the agreement with Interferon Medical Use in Collina d'Oro, Switzerland - a 100% affiliate...
New Coupling Agents from Bachem
The coupling reaction is the critical step in peptide synthesis. In particular, the solid-phase approach relies on rapid peptide bond formation and complete conversion with a minimum of...
New Products from Bachem – Bioactive Molecules, Synthetic RANTES Peptides, LHRH Impurities and a Range of New Immunology Products
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include a number of...
Bachem - Your Partner for Opioid Peptides
Several families of endogenous opioid peptides, the endorphins, enkephalins and dynorphins, have been identified in the mammalian central nervous system. The peptides of these families contain...
Bachem Presents 31 New Products
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include several...
Bachem's New Apelin Products
The 36-peptide apelin-36, which was originally detected in bovine stomach extracts, turned out to be the specific endogenous ligand of the orphan G protein-coupled receptor APJ. APJ has been...
Stephan Schindler to Become New CFO of Bachem Group
Bachem has announced that Stephan Schindler, currently the head of Finance & Control Switzerland at DSM Nutritional Products, Kaiseraugst, will succeed Michael Hüsler as CFO of the...
18 New Products are Available from Bachem
Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include...
Annual General Meeting Elects New Member of the Board of Directors
Bachem has announced that at the annual general meeting of Bachem Holding on 22 April 2009 Dr Jürgen Brokatzky-Geiger was elected as a new member of the board of directors by a vast...
Bachem - Your Partner for Peptide Toxins
Peptide and protein toxins are widespread in the animal kingdom as well as in microorganisms and fungi.Their unique properties make them valuable tools in various areas of research. The...
Bachem and Debiopharm Sign Follow-Up Contract for Long-Term Supply of Triptorelin Pamoate
Bachem and Debiopharm has announced the conclusion of a follow-up agreement for the long-term supply of Triptorelin Pamoate. Bachem has been supplying Triptorelin Pamoate, the active...
Bachem Announces Financial Results for the Business Year 2008
In the business year 2008 the Bachem Group achieved sales of CHF195 million. Compared with the previous year, this corresponds to a 2% sales growth in local currencies or a 1.7% sales decline...
Bachem Enlarges Corporate Executive Committee
Bachem announced today that Dr. Lester Mills will become the fourth member of the company’s Corporate Executive Committee on 1 January 2009. Lester Mills will be responsible for global...
Record Year for Bachem at all Levels in 2007
Sales grow to CHF198.3 million – up 17.0% in local currencies and 15.5% in CHF respectively Operating profit up 29.9%, net income up 37% Operating margin rises sharply to 36.5%, net income...
Action Pharma and Bachem Cooperate on AP214 - Now Ready to Enter Phase 2 Clinical Trials
Action Pharma A/S and Bachem (SWX: BANB) today announced their cooperation on AP214, Action Pharma’s lead compound, about to enter Phase 2 clinical trials in post-surgical organ failure....
Bachem Production Facilities Licensed for the Manufacture of APIs for the Japanese Market
Bachem announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted the company a manufacturing license in conformity with the new regulations. The license...
